Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alto Neuroscience, Inc. ( (ANRO) ) has provided an update.
On August 12, 2025, Alto Neuroscience, Inc. announced the appointment of Dr. Raymond Sanchez to its Board of Directors, expanding the board from five to six members. Dr. Sanchez brings over 20 years of experience in the life sciences industry, enhancing Alto’s strategic direction in the biotechnology and pharmaceutical sectors. Additionally, Alto reported its second quarter 2025 financial results, highlighting significant progress in its precision psychiatry pipeline, including the acquisition of ALTO-207, a promising treatment for treatment-resistant depression. The company maintains a strong cash position to support its operations and upcoming clinical trials, reinforcing its commitment to addressing unmet needs in neuropsychiatric disorders.
The most recent analyst rating on (ANRO) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
Alto Neuroscience, Inc. faces significant financial challenges with zero revenue, increasing losses, and negative cash flows, reflecting in a low financial performance score. Despite some technical indicators suggesting short-term upward momentum, the stock’s valuation remains risky due to a negative P/E ratio and lack of dividends, resulting in an overall low stock score.
To see Spark’s full report on ANRO stock, click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders. The company is engaged in advancing a pipeline of clinical-stage product candidates, with a strong emphasis on utilizing biomarkers to guide drug development and improve patient outcomes.
Average Trading Volume: 240,234
Technical Sentiment Signal: Buy
Current Market Cap: $86.09M
For an in-depth examination of ANRO stock, go to TipRanks’ Overview page.